School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Amelia Langston MD

  • Department of Hematology and Medical Oncology
    Professor
  • (404) 778-1900
  • alangst@emory.edu
Head shot of Amelia Langston

Academic Appointment

  • Professor of Hematology and Medical Oncology, Clinical Track, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University

Education

Degrees

  • BA from Williams College
  • MD from Washington University School of Medicine

Research

Focus

  • My research focuses on novel strategies for autologous and allogeneic stem cell transplantation. I also study prevention methods and treatment of opportunistic infections in immunocompromised patients, along with the use of biologically targeted agents for antileukemic therapy.

Publications

  • The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities.
    Transplant Cell Ther Volume: 31 Page(s): 109.e1 - 109.e13
    02/01/2025 Authors: Takahashi T; Watkins B; Bratrude B; Neuberg D; Hebert K; Betz K; Yu A; Choi SW; Davis J; Duncan C
  • (Donor) age is more than just a number.
    Bone Marrow Transplant Volume: 60 Page(s): 1 - 2
    01/01/2025 Authors: Vale C; Langston AA
  • Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation.
    Blood Volume: 144 Page(s): 1834 - 1845
    10/24/2024 Authors: Kean LS; Burns LJ; Kou TD; Kapikian R; Lozenski K; Langston A; Horan JT; Watkins B; Qayed M; Bratrude B
  • Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
    J Clin Apher Volume: 39 Page(s): e22127
    06/01/2024 Authors: Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T
  • Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD.
    Bone Marrow Transplant Volume: 59 Page(s): 680 - 687
    05/01/2024 Authors: Gorfinkel L; Raghunandan S; Watkins B; Hebert K; Neuberg DS; Bratrude B; Betz K; Yu A; Choi SW; Davis J
  • Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association.
    Circulation Volume: 149 Page(s): e1113 - e1127
    04/16/2024 Authors: Hayek SS; Zaha VG; Bogle C; Deswal A; Langston A; Rotz S; Vasbinder A; Yang E; Okwuosa T; American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; and the Council on Cardiovascular and Stroke Nursing
  • Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies.
    Bone Marrow Transplant Volume: 58 Page(s): 1264 - 1266
    11/01/2023 Authors: Raghunandan S; Qayed M; Watkins BK; Graiser M; Gorfinkel L; Westbrook A; Gillespie S; Bratrude B; Petrovic A; Suessmuth Y
  • Abatacept for the prevention of graft versus host disease in pediatric patients receiving 7/8 HLA-mismatched unrelated transplant for hematologic malignancies: a real-world analysis.
    Bone Marrow Transplant Volume: 58 Page(s): 1260 - 1263
    11/01/2023 Authors: Raghunandan S; Gorfinkel L; Bratrude B; Suessmuth Y; Hebert K; Neuberg D; Williams KM; Schoettler ML; Langston AA; Kean LS
  • Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
    Blood Adv Volume: 7 Page(s): 5189 - 5198
    09/12/2023 Authors: Al Malki MM; London K; Baez J; Akahoshi Y; Hogan WJ; Etra A; Choe H; Hexner E; Langston A; Abhyankar S
  • Higher abatacept exposure after transplant decreases acute GVHD risk without increasing adverse events.
    Blood Volume: 142 Page(s): 700 - 710
    08/24/2023 Authors: Takahashi T; Al-Kofahi M; Jaber M; Bratrude B; Betz K; Suessmuth Y; Yu A; Neuberg DS; Choi SW; Davis J
  • Abatacept for the prevention of GVHD in patients receiving mismatched unrelated transplants: a real-world analysis.
    Blood Adv Volume: 7 Page(s): 4395 - 4399
    08/22/2023 Authors: Raghunandan S; Gorfinkel L; Graiser M; Bratrude B; Suessmuth Y; Gillespie S; Westbrook AL; Williams KM; Schoettler ML; Kean LS
  • Passenger pathogens on physicians.
    Am J Infect Control Volume: 51 Page(s): 807 - 811
    07/01/2023 Authors: Funk CR; Ravindranathan S; Matelski A; Zhang H; Taylor C; Chandrasekaran S; Arellano M; Langston AA; Joseph N; Waller EK
  • Effective treatment of low-risk acute GVHD withitacitinib monotherapy.
    Blood Volume: 141 Page(s): 481 - 489
    02/02/2023 Authors: Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J
  • Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantation.
    Blood Adv Volume: 6 Page(s): 746 - 749
    02/08/2022 Authors: Qayed M; Watkins B; Gillespie S; Bratrude B; Betz K; Choi SW; Davis J; Duncan C; Giller R; Grimley M
  • Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
    Front Immunol Volume: 13 Page(s): 959658
    01/01/2022 Authors: Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
  • Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
    Blood Volume: 138 Page(s): 2278 - 2289
    12/02/2021 Authors: Cutler C; Lee SJ; Arai S; Rotta M; Zoghi B; Lazaryan A; Ramakrishnan A; DeFilipp Z; Salhotra A; Chai-Ho W
  • Cytomegalovirus immunoglobulin G: passive transfer or prior infection?
    Br J Haematol Volume: 195 Page(s): 11 - 12
    10/01/2021 Authors: Byrne M; Langston AA; Booth GS
  • A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies.
    Transplant Cell Ther Volume: 27 Page(s): 837.e1 - 837.e10
    10/01/2021 Authors: Saber W; Steinert P; Zhang M-J; Chen M; Pope A; Keating A; Wingard JR; Ballen K; Stiff P; Perales M-A
  • Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
    Blood Adv Volume: 5 Page(s): 3528 - 3539
    09/01/2021 Authors: Herrera AF; Ahn KW; Litovich C; Chen Y; Assal A; Bashir Q; Bayer R-L; Coleman M; DeFilipp Z; Farhadfar N
  • Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.
    J Clin Oncol Volume: 39 Page(s): 1865 - 1877
    06/10/2021 Authors: Watkins B; Qayed M; McCracken C; Bratrude B; Betz K; Suessmuth Y; Yu A; Sinclair S; Furlan S; Bosinger S
  • Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
    Haematologica Volume: 106 Page(s): 1599 - 1607
    06/01/2021 Authors: Cooper JP; Storer BE; Granot N; Gyurkocza B; Sorror ML; Chauncey TR; Shizuru J; Franke G-N; Maris MB; Boyer M
  • Pure red blood cell aplasia: patient management pitfalls in major ABO-incompatible haematopoietic cell transplantation.
    Br J Haematol Volume: 193 Page(s): 701 - 702
    05/01/2021 Authors: Booth GS; Savani BN; Langston AA
  • Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia.
    JCO Oncol Pract Volume: 17 Page(s): e497 - e505
    04/01/2021 Authors: Jillella AP; Arellano ML; Gaddh M; Langston AA; Heffner LT; Winton EF; McLemore ML; Zhang C; Caprara CR; Simon KS
  • Human Adenovirus 11 in 2 Renal Transplant Recipients: Suspected Donor-Derived Infection.
    Open Forum Infect Dis Volume: 8 Page(s): ofab092
    03/01/2021 Authors: Sherman AC; Lu X; Schneider E; Langston A; Ellis CL; Pastan S; Bhatnagar J; Reagan-Steiner S; Annambhotla P; Lindstrom S
  • A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.
    Volume: 33 Page(s): 100787
    03/01/2021 Authors: Ljungman P; Bermudez A; Logan AC; Kharfan-Dabaja MA; Chevallier P; Martino R; Wulf G; Selleslag D; Kakihana K; Langston A
  • Why does the place where the allogeneic transplant patient calls home matter?
    Cancer Volume: 127 Page(s): 510 - 511
    02/15/2021 Authors: Langston AA
  • Spatiotemporal single-cell profiling reveals that invasive and tissue-resident memory donor CD8+ T cells drive gastrointestinal acute graft-versus-host disease.
    Sci Transl Med Volume: 13
    01/13/2021 Authors: Tkachev V; Kaminski J; Potter EL; Furlan SN; Yu A; Hunt DJ; McGuckin C; Zheng H; Colonna L; Gerdemann U
  • Allocating Scarce Health Care Resources During Pandemics: Making the Case for Patients with Advanced and Metastatic Cancer.
    Oncologist Volume: 25 Page(s): e1586 - e1588
    10/01/2020 Authors: Langston AA; Quest TE; Abernethy ER; Campbell GP; Owonikoko TK; Pentz RD
  • Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cancer Volume: 126 Page(s): 1235 - 1242
    03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM
  • Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
    Bone Marrow Transplant Volume: 55 Page(s): 172 - 181
    01/01/2020 Authors: Shadman M; Maloney DG; Storer B; Sandmaier BM; Chauncey TR; Smedegaard Andersen N; Niederwieser D; Shizuru J; Bruno B; Pulsipher MA
  • ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
    Hematol Rep Volume: 11 Page(s): 8395
    11/29/2019 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangaonkar A; Kota VK
  • Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
    Clin Cancer Res Volume: 25 Page(s): 5143 - 5155
    08/15/2019 Authors: Kim HT; Ahn KW; Hu Z-H; Davids MS; Volpe VO; Antin JH; Sorror ML; Shadman M; Press O; Pidala J
  • Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Lancet Haematol Volume: 6 Page(s): e409 - e418
    08/01/2019 Authors: Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA
  • Acute Myeloid Leukemia in Young Adults: Does Everyone Need a Transplant?
    J Oncol Pract Volume: 15 Page(s): 315 - 320
    06/01/2019 Authors: Roberts MMSc D; Langston AA; Heffner LT
  • Follow-up to comment on "Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Thrombophilia: Systematic Review and Meta-Analysis".
    J Thromb Haemost Volume: 17 Page(s): 1007 - 1009
    06/01/2019 Authors: Elsebaie MAT; Van Es N; Langston A; Bller HR; Gaddh M
  • Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study.
    Clin Infect Dis Volume: 68 Page(s): 1255 - 1264
    04/08/2019 Authors: Papanicolaou GA; Silveira FP; Langston AA; Pereira MR; Avery RK; Uknis M; Wijatyk A; Wu J; Boeckh M; Marty FM
  • Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis.
    Volume: 17 Page(s): 645 - 656
    04/01/2019 Authors: Elsebaie MAT; van Es N; Langston A; Bller HR; Gaddh M
  • Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Cancer Volume: 125 Page(s): 185 - 193
    01/15/2019 Authors: Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR
  • Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report.
    Int J Mol Sci Volume: 19
    12/19/2018 Authors: Funk CR; Petersen CT; Jagirdar N; Ravindranathan S; Jaye DL; Flowers CR; Langston A; Waller EK
  • Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.
    J Clin Oncol Volume: 36 Page(s): 3043 - 3054
    10/20/2018 Authors: Taplitz RA; Kennedy EB; Bow EJ; Crews J; Gleason C; Hawley DK; Langston AA; Nastoupil LJ; Rajotte M; Rolston KV
  • TREATMENT OF VENOUS THROMBOEMBOLISM DURING INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE
    Volume: 93 Page(s): E51 - E51
    09/01/2018 Authors: Patel B; Cheng E; McLemore M; Arellano M; Heffner LT; Winton EF; Bodo I; Langston A; Kota V; Gaddh M
  • Ruxolitinib: a steroid sparing agent in chronic graft-versus-host disease.
    Bone Marrow Transplant Volume: 53 Page(s): 826 - 831
    07/01/2018 Authors: Khoury HJ; Langston AA; Kota VK; Wilkinson JA; Pusic I; Jillella A; Bauer S; Kim AS; Roberts D; Al-Kadhimi Z
  • Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.
    J Clin Oncol Volume: 36 Page(s): 1443 - 1453
    05/10/2018 Authors: Taplitz RA; Kennedy EB; Bow EJ; Crews J; Gleason C; Hawley DK; Langston AA; Nastoupil LJ; Rajotte M; Rolston K
  • Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
    Biol Blood Marrow Transplant Volume: 24 Page(s): 973 - 982
    05/01/2018 Authors: Hosoba S; Waller EK; Shenvi N; Graiser M; Easley KA; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Josephson CD
  • Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma Volume: 59 Page(s): 837 - 843
    04/01/2018 Authors: Dhere V; Edelman S; Waller EK; Langston A; Graiser M; Connolly EC; Switchenko JM; Esiashvili N; Khan MK
  • Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
    Volume: 24 Page(s): S135 - S136
    03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S
  • Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
    Cancer Volume: 124 Page(s): 816 - 825
    02/15/2018 Authors: Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN
  • Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation.
    Hematol Rep Volume: 9 Page(s): 7083
    09/26/2017 Authors: Jillella AP; Arellano ML; Heffner LT; Gaddh M; Langston AA; Khoury HJ; Mangoankar A; Kota VK
  • Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.
    Volume: 52 Page(s): 1304 - 1310
    09/01/2017 Authors: Al-Kadhimi Z; Gul Z; Abidi M; Lum LG; Deol A; Chen W; Jang H; Ozust C; Langston A; Waller E
  • Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention
    BONE MARROW TRANSPLANTATION Volume: 52 Page(s): 1304 - 1310
    09/01/2017 Authors: Al-Kadhimi Z; Gul Z; Abidi M; Lum LG; Deol A; Chen W; Jang H; Ozust C; Langston A; Waller E
  • Opportunity for Collaboration Between Radiation Injury Treatment Network Centers and Medical Toxicology Specialists.
    South Med J Volume: 110 Page(s): 497 - 501
    08/01/2017 Authors: Davlantes E; Shartar S; Venero J; Steck A; Langston A; Kazzi ZN
  • Dose dependent association of early red blood cell transfusion with increased risk of graft versus host disease and worse survival after allogeneic hematopoietic stem cell transplantation
    Volume: 52 Page(s): S207 - S208
    07/01/2017 Authors: Waller EK; Hosoba S; Al-Kadhimi Z; Andoh A; Antun AG; Barclay S; Easley KA; Josephson CD; Khoury HJ; Koff JL
  • Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 17S Page(s): S96 - S99
    07/01/2017 Authors: Staton AD; Langston AA
  • Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Cancer Volume: 123 Page(s): 2482 - 2488
    07/01/2017 Authors: Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A
  • Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study.
    Infect Control Hosp Epidemiol Volume: 38 Page(s): 651 - 657
    06/01/2017 Authors: Shah NN; McClellan W; Flowers CR; Lonial S; Khoury H; Waller EK; Langston A; Nooka AK
  • Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period.
    Transpl Infect Dis Volume: 19
    02/01/2017 Authors: Aldrete SDM; Kraft CS; Magee MJ; Chan A; Hutcherson D; Langston AA; Greenwell BI; Burd EM; Friedman-Moraco R
  • Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
    Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
    01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR
  • Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial
    Volume: 128
    12/02/2016 Authors: Sandmaier BM; Maloney DG; Storer BE; Olesen G; Maris MB; Gutman JA; Petersen SL; Langston A; Chauncey T; Bethge W
  • Total Body Irradiation-Based Conditioning (TBI) Versus Chemotherapy-Based Conditioning (ChBC) for Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) for Acute Leukemia
    Volume: 96 Page(s): E493 - E494
    10/01/2016 Authors: Edelman S; Waller EK; Graiser M; Langston AA; Dhere V; Mikell JL; Switchenko JM; Esiashvili N; Khan MK
  • Total Body Irradiation-Based Conditioning (TBI) Versus Chemotherapy-Based Conditioning (ChBC) for Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) for Acute Leukemia
    Volume: 96 Page(s): E493 - E494
    10/01/2016 Authors: Edelman S; Waller EK; Graiser M; Langston AA; Dhere V; Mikell JL; Switchenko JM; Esiashvili N; Khan MK
  • Total Body Irradiation-Based Conditioning (TBI) Versus Chemotherapy-Based Conditioning (ChBC) for Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) for Acute Leukemia.
    Int J Radiat Oncol Biol Phys Volume: 96 Page(s): E493 - E494
    10/01/2016 Authors: Edelman S; Waller EK; Graiser M; Langston AA; Dhere V; Mikell JL; Switchenko JM; Esiashvili N; Khan MK
  • Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
    Clin Lymphoma Myeloma Leuk Volume: 16 Page(s): 466 - 471.e1
    08/01/2016 Authors: DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R
  • DECREASING EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN AN ACADEMIC CENTER IN THE US BY USING A SIMPLIFIED TREATMENT ALGORITHM AND DEDICATED APL EXPERTS
    Volume: 101 Page(s): 675 - 676
    06/01/2016 Authors: Jillella A; Mody M; Harpaul G; Arellano M; Khoury H; Al-Kadhimi Z; McLemore M; Winton E; Gaddh M; Heffner L
  • Costs associated with induction chemotherapy in adult acute myeloid leukemia (AML) managed in a tertiary care specialized unit.
    Volume: 34
    05/20/2016 Authors: Gleason S; Howard DH; Liu Y; Goldstein DA; Arellano ML; Jillella AP; Gaddh M; Kota V; Winton EF; Heffner LT
  • Tailored Post-Transplant Maintenance with Tyrosine Kinase Inhibitors for High-Risk Philadelphia Chromosome-Positive Leukemia
    Volume: 22 Page(s): S313 - S313
    03/01/2016 Authors: DeFilipp Z; Langston AA; Kota VK; Al-Kadhimi Z; Jillella AP; Waller EK; Khoury HJ
  • Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease.
    J Antimicrob Chemother Volume: 71 Page(s): 718 - 726
    03/01/2016 Authors: Cornely OA; Duarte RF; Haider S; Chandrasekar P; Helfgott D; Jimnez JL; Candoni A; Raad I; Laverdiere M; Langston A
  • Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.
    Bone Marrow Transplant Volume: 51 Page(s): 277 - 282
    02/01/2016 Authors: Riches ML; Trifilio S; Chen M; Ahn KW; Langston A; Lazarus HM; Marks DI; Martino R; Maziarz RT; Papanicolou GA
  • Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.
    Biol Blood Marrow Transplant Volume: 22 Page(s): 359 - 370
    02/01/2016 Authors: Young J-AH; Logan BR; Wu J; Wingard JR; Weisdorf DJ; Mudrick C; Knust K; Horowitz MM; Confer DL; Dubberke ER
  • Referral Patterns and Clinical Outcomes for Transplant-Eligible Lymphoma and Myeloma Patients Evaluated at an Urban County Hospital.
    J Stem Cell Res Ther Volume: 6
    01/01/2016 Authors: Yun HD; Dossul T; Bernal-Mizrachi L; Switchenko J; Ndibe C; Ibraheem A; Dixon MD; Langston AA; Nooka AK; Flowers CR
  • A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma
    Volume: 126
    12/03/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston A; Flowers C; Devine SM; Blum KA
  • Ruxolitinib As Sparing Agent for Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD)
    Volume: 126
    12/03/2015 Authors: Khoury HJ; Kota V; Arellano M; Bauer SL; Jillella AP; Langston A; Al-Kadhimi Z; DeFilipp Z; Kim AS; Winton EF
  • Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant
    Volume: 126
    12/03/2015 Authors: Lee MJ; Switchenko J; Thomas JS; Koff JL; Nastoupil L; Lechowicz MJ; Langston AA; Flowers C; Cohen JB
  • Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma
    Volume: 126
    12/03/2015 Authors: Chandra P; Akinbobuyi O; Liao A; Arora J; Chen Z; Lechowicz MJ; Langston AA; Kowalsky J; Cohen JB; Flowers CR
  • Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA
    Volume: 126
    12/03/2015 Authors: Jillella A; Arellano M; Bashey A; Vidito SI; Stuart RK; Leung C; Sitchenko K; Gaddh M; Heffner LT; Kolhe RB
  • Survival of Patients Diagnosed with Primary Refractory and Relapsed Acute Myeloid Leukemia from 2008-2012: A Single Institution Experience
    Volume: 126
    12/03/2015 Authors: Zeichner SB; Gleason S; Antun AG; Langston A; Heffner LT; Kota VK; Gaddh M; Arellano M
  • A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Volume: 171 Page(s): 539 - 546
    11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ
  • Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Cancer Volume: 121 Page(s): 3709 - 3716
    10/15/2015 Authors: Vaughn JE; Sorror ML; Storer BE; Chauncey TR; Pulsipher MA; Maziarz RT; Maris MB; Hari P; Laport GG; Franke GN
  • Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Transfusion Volume: 55 Page(s): 2351 - 2357
    10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C
  • Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
    09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A
  • CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR repertoire.
    Blood Volume: 125 Page(s): 3835 - 3850
    06/18/2015 Authors: Suessmuth Y; Mukherjee R; Watkins B; Koura DT; Finstermeier K; Desmarais C; Stempora L; Horan JT; Langston A; Qayed M
  • Bloodless transplants for multiple myeloma are feasible and yield similar results as matched controls.
    Volume: 33
    05/20/2015 Authors: Obidike CO; Nooka AK; Kaufman JL; Heffner LT; Langston AA; Lonial S
  • A phase I study of gemcitabine and bendamustine in relapsed/refractory Hodgkin's lymphoma
    Volume: 33
    05/20/2015 Authors: Cohen JB; Wei L; Maddocks KJ; Heffner LT; Langston AA; Flowers C; Devine SM; Blum KA
  • Improving Test Utilization for Chimerism Analysis After Hematopoietic Stem Cell Transplantation
    Volume: 143 Page(s): A48 - A48
    05/01/2015 Authors: Stelton C; Geller R; Waller E; Langston A; Gebel H; Jaye D
  • Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning
    Volume: 21 Page(s): S88 - S89
    02/01/2015 Authors: Vaughn J; Sorror ML; Chauncey T; Pulsipher MA; Maziarz RT; Maris MB; Hari PN; Laport GG; Franke G-N; Agura E
  • Exhaustive TCR Deep Sequencing Reveals That CMV Reactivation Fundamentally Resets Immune Reconstitution after Transplant and Results in Significant Deficits in the Effector Memory TCR Repertoire
    Volume: 21 Page(s): S69 - S70
    02/01/2015 Authors: Suessmuth Y; Koura D; Finstermeier K; Desmarais C; Horan J; Langston A; Qayed M; Khoury HJ; Watkins BK; Robins H
  • Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
    Leuk Lymphoma Volume: 56 Page(s): 383 - 389
    02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L
  • Non-Inferior Clinical Outcomes for Lymphoma and Myeloma Patients Referred from a County Hospital to an Academic Transplant Center for Autologous Stem Cell Transplantation
    Volume: 124
    12/06/2014 Authors: Yun HD; Dossul T; Bernal-Mizrachi L; Switchenko J; Ndibe C; Ibraheem A; Langston A; Pentz R; Waller EK
  • Dermato-neuro syndrome in a patient treated with autologous stem cell transplant for scleromyxedema.
    Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e213 - e215
    12/01/2014 Authors: Shams SR; Goldstein DA; Kaufman JL; MacKelfresh J; Flowers CR; Langston AA
  • Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.
    Antimicrob Agents Chemother Volume: 58 Page(s): 5758 - 5765
    10/01/2014 Authors: Duarte RF; Lpez-Jimnez J; Cornely OA; Laverdiere M; Helfgott D; Haider S; Chandrasekar P; Langston A; Perfect J; Ma L
  • A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.
    Haematologica Volume: 99 Page(s): 1624 - 1631
    10/01/2014 Authors: Kornblit B; Maloney DG; Storer BE; Maris MB; Vindelv L; Hari P; Langston AA; Pulsipher MA; Bethge WA; Chauncey TR
  • Incidence and geographic distribution of adult acute leukemia in the state of Georgia.
    South Med J Volume: 107 Page(s): 497 - 500
    08/01/2014 Authors: El Rassi F; Ward KC; Flowers CR; Heffner LT; Waller EK; Winton EF; Vaughn J; Hill BG; Langston A; Nooka A
  • CMV Reactivation Drives Accelerated Immune Aging After Bone Marrow Transplant
    Volume: 98 Page(s): 178 - 179
    07/15/2014 Authors: Suessmuth Y; Cheeseman J; Stempora L; Garrett A; Finstermeier K; Desmarais C; Langston A; Kirk A; Mehta A; Kean L
  • Sensitivity and specificity of cerebrospinal fluid flow cytometry for the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma.
    Leuk Lymphoma Volume: 55 Page(s): 1498 - 1500
    07/01/2014 Authors: Mitri Z; Siddiqui MT; El Rassi F; Holden JT; Heffner LT; Langston A; Waller EK; Winton E; McLemore M; Bernal-Mizrachi L
  • CMV Reactivation Drives Accelerated Immune Aging After Bone Marrow Transplant
    Volume: 14 Page(s): 178 - 179
    06/01/2014 Authors: Suessmuth Y; Cheeseman J; Stempora L; Garrett A; Finstermeier K; Desmarais C; Langston A; Kirk A; Mehta A; Kean L
  • Similar survival for patients undergoing reduced-intensity total body irradiation (TBI) versus myeloablative TBI as conditioning for allogeneic transplant in acute leukemia.
    Int J Radiat Oncol Biol Phys Volume: 89 Page(s): 360 - 369
    06/01/2014 Authors: Mikell JL; Waller EK; Switchenko JM; Rangaraju S; Ali Z; Graiser M; Hall WA; Langston AA; Esiashvili N; Khoury HJ
  • Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
    Biol Blood Marrow Transplant Volume: 20 Page(s): 852 - 857
    06/01/2014 Authors: Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S
  • Survival trends of myeloma patients in the new millennium.
    Volume: 32
    05/20/2014 Authors: Gleason C; Nooka AK; Langston AA; Shah NN; Kaufman JL; Lonial S
  • Causes of mortality in patients with plasma cell disorders.
    Volume: 32
    05/20/2014 Authors: Nooks AK; Kaufman JL; Langston AA; Lonial S
  • Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series.
    Clin Lymphoma Myeloma Leuk Volume: 14 Page(s): e59 - e63
    04/01/2014 Authors: Nooka AK; Harvey RD; Langston A; Collins H; Lonial S; Kaufman JL
  • Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.
    Leukemia Volume: 28 Page(s): 690 - 693
    03/01/2014 Authors: Nooka AK; Kaufman JL; Muppidi S; Langston A; Heffner LT; Gleason C; Casbourne D; Saxe D; Boise LH; Lonial S
  • Simplified Technique for Administration of High Dose Melphalan
    Volume: 20 Page(s): S291 - S292
    02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A
  • Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
    Bone Marrow Transplant Volume: 49 Page(s): 185 - 189
    02/01/2014 Authors: Langston AA; Prichard JM; Muppidi S; Nooka A; Lechowicz MJ; Lonial S; Sinha R; Graiser M; Kaufman JL; Khoury HJ
  • Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
    12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT
  • Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.
    Cancer Volume: 119 Page(s): 4119 - 4128
    12/01/2013 Authors: Nooka AK; Kaufman JL; Behera M; Langston A; Waller EK; Flowers CR; Gleason C; Boise LH; Lonial S
  • Using Serum Free Light Chain (SFLC) Ratio and Serum Protein Electrophoresis (SPEP) As a Substitute For 24-Hour Urine Studies In Myeloma Patients
    Volume: 122
    11/15/2013 Authors: Shah NN; Nooka AK; Harvey D; Kaufman JL; Langston A; Nickleach D; Gleason C; Heffner LT; Boise LH; Lonial S
  • Evaluating Risk Factors and Outcomes For Clostridium Difficile Infection (CDI) In Stem Cell Transplant (SCT) Recipients
    Volume: 122
    11/15/2013 Authors: Shah NN; Nooka AK; Kaufman JL; Casbourne D; Hutcherson D; Maynard R; Waller EK; Lonial S; Langston A
  • Indications For Hospital Admissions and Outcomes Of Hospitalization Among Multiple Myeloma Patients In The U.S: Data From National Inpatient Sample
    Volume: 122
    11/15/2013 Authors: Nooka AK; Kaufman JL; Shah NN; Langston A; Collins H; Boise LH; Lonial S
  • Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT)
    Volume: 122
    11/15/2013 Authors: Gowda S; Langston A; Kaufman JL; Shah NN; Lechowicz MJ; Boise LH; Lonial S; Nooka AK
  • Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies.
    Cancer Volume: 119 Page(s): 3784 - 3787
    11/01/2013 Authors: Antun AG; Gleason S; Arellano M; Langston AA; McLemore ML; Gaddh M; el Rassi F; Bernal-Mizrachi L; Galipeau J; Heffner LT
  • In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 1638 - 1649
    11/01/2013 Authors: Koura DT; Horan JT; Langston AA; Qayed M; Mehta A; Khoury HJ; Harvey RD; Suessmuth Y; Couture C; Carr J
  • Similar Survival for Patients Undergoing Reduced-Intensity TBI Versus Myeloablative TBI as Conditioning for Allogeneic Transplant in Acute Leukemia
    Volume: 87 Page(s): S558 - S558
    10/01/2013 Authors: Mikell JL; Waller EK; Rangaraju S; Switchenko JM; Ali Z; Graiser M; Hall WA; Langston AA; Esiashvili N; Khan MK
  • Advances in hematopoietic stem cell transplantation in chronic myeloid leukemia.
    Discov Med Volume: 16 Page(s): 179 - 186
    10/01/2013 Authors: Veldman R; El Rassi F; Holloway S; Langston A; Khoury HJ
  • Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
    09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S
  • Inherited predisposition to multiple myeloma.
    Ther Adv Hematol Volume: 4 Page(s): 291 - 297
    08/01/2013 Authors: Koura DT; Langston AA
  • ELIMINATING THE NEED FOR 24-HOUR URINE STUDIES IN PHASE I MYELOMA PATIENTS
    Volume: 98 Page(s): 598 - 598
    06/12/2013 Authors: Shah N; Kaufman J; Langston A; Waller E; Boise L; Harvey R; Lonial S; Nooka A
  • Outcomes of hematopoietic stem cell transplant recipients admitted to the medical intensive care unit.
    Volume: 31
    05/20/2013 Authors: Duc QT; Langston AA; Waller EK; Simon M; Gleason C; Casbourne D; Fisher M; Kaufman JL; Flowers C; Lonial S
  • Survival outcomes of plasma cell leukemia (PCL) in the United States: A SEER analysis
    Volume: 31
    05/20/2013 Authors: Ravipati HP; Kaufman JL; Langston AA; Boise L; Flowers C; Lonial S; Nooka AK
  • Early versus delayed autologous stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for newly diagnosed multiple myeloma (MM)
    Volume: 31
    05/20/2013 Authors: Nooka AK; Langston AA; Waller EK; Heffner LT; Gleason C; Muppidi S; Watson M; Casbourne D; Boise L; Kaufman JL
  • Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation.
    J Pediatr Hematol Oncol Volume: 35 Page(s): e149 - e152
    05/01/2013 Authors: Qayed M; Langston A; Chiang K-Y; August K; Hilinski JA; Cole CR; Rogatko A; Bostick RM; Horan JT
  • Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
    J Clin Oncol Volume: 31 Page(s): 1530 - 1538
    04/20/2013 Authors: Storb R; Gyurkocza B; Storer BE; Sorror ML; Blume K; Niederwieser D; Chauncey TR; Pulsipher MA; Petersen FB; Sahebi F
  • Single centre pharmacoeconomic analysis of palifermin in autologous stem cell transplantation
    Volume: 48 Page(s): S453 - S453
    04/01/2013 Authors: Johnson HR; Nooka A; Kaufman J; Flowers C; Langston A; Graiser M; Plummer T; Lonial S; Waller E
  • Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 460 - 467
    03/01/2013 Authors: Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
  • Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
    J Clin Oncol Volume: 31 Page(s): 794 - 810
    02/20/2013 Authors: Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KVI
  • Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
    Volume: 19 Page(s): S191 - S191
    02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M
  • A First-in-Disease Trial of in Vivo Costimulation Blockade for GVHD Prevention: The Addition of Abatacept to Standard GVHD Prophylaxis Controls Early CD4+T Cell Proliferation and is Associated with Low Rates of Severe Acute GVHD
    Volume: 19 Page(s): S327 - S328
    02/01/2013 Authors: Tiwari D; Horan J; Langston A; Qayed M; Carr J; Renfroe H; Couture C; Khoury HJ; Robertson J; Harvey D
  • Reanalysis of TransVax immunogenicity.
    Lancet Infect Dis Volume: 13 Page(s): 18
    01/01/2013 Authors: Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Smith LR; Rolland AP; Kenney RT
  • A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
    Transfusion Volume: 53 Page(s): 76 - 84
    01/01/2013 Authors: Kaufman JL; Flowers CR; Rados KD; Calandra GB; Vose JM; Hewes LB; Lonial S; Langston AA; Khoury HJ; Lechowicz MJ
  • Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
    Volume: 120
    11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
  • Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
    Volume: 120
    11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
  • Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Cancer Volume: 118 Page(s): 5278 - 5282
    11/01/2012 Authors: Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
  • A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
    Cancer Volume: 118 Page(s): 3556 - 3564
    07/15/2012 Authors: Khoury HJ; Garcia-Manero G; Borthakur G; Kadia T; Foudray MC; Arellano M; Langston A; Bethelmie-Bryan B; Rush S; Litwiler K
  • Efscalefect of lenalidomide, bortezomib, and dexamethasone (RVD) induction therapy in transplant-eligible patients (Pts) with newly diagnosed multiple myeloma (MM) on CR rates and survival.
    Volume: 30
    05/20/2012 Authors: Gleason C; Nooka AK; Muppidi S; Heffner LT; Steuer CE; Kumar M; Casbourne D; Langston AA; Watson M; Boise L
  • Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.
    Antimicrob Agents Chemother Volume: 56 Page(s): 2652 - 2658
    05/01/2012 Authors: Cornely OA; Helfgott D; Langston A; Heinz W; Vehreschild J-J; Vehreschild MJGT; Krishna G; Ma L; Huyck S; McCarthy MC
  • CD28-Directed Costimulation Blockade with Abatacept To Prevent GvHD during High-Risk Unrelated BMT: A First-in-Disease Trial
    Volume: 12 Page(s): 34 - 34
    05/01/2012 Authors: Kean L; Tiwari D; Mehta A; Sen S; Robertson J; Carr J; Renfroe H; Langston A; Waller E; Horan J
  • A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis Volume: 12 Page(s): 290 - 299
    04/01/2012 Authors: Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
  • BI-MODAL AGE DISTRIBUTION OF PATIENTS WITH RELAPSED HODGKIN LYMPHOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION CORRELATES WITH MARKEDLY INFERIOR SURVIVAL AMONG PATIENTS AGE 35 YEARS AND OLDER
    Volume: 18 Page(s): S296 - S296
    02/01/2012 Authors: Sharma A; Duan M; Chowdhury R; Graiser M; Zhang H; Langston A; Lonial S; Flowers CR; Haight A; Waller EK
  • CD28-DIRECTED T CELL COSTIMULATION BLOCKADE WITH ABATACEPT TO PREVENT GVHD DURING HIGH-RISK UNRELATED HSCT: A FIRST-IN-DISEASE TRIAL
    Volume: 18 Page(s): S365 - S365
    02/01/2012 Authors: Kean LS; Langston A; Qayed M; Khoury J; Tiwari D; Couture C; Renfroe H; Sen S; Robertson I; Waller EK
  • Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
    Am J Health Syst Pharm Volume: 69 Page(s): 149 - 156
    01/15/2012 Authors: O'Sullivan AK; Weinstein MC; Pandya A; Thompson D; Langston AA; Perfect JR; Papadopoulos G
  • High-dose cytarabine induction is well tolerated and active in patients with de novo acute myeloid leukemia older than 60 years.
    Cancer Volume: 118 Page(s): 428 - 433
    01/15/2012 Authors: Arellano M; Winton E; Pan L; Lima L; Tighiouart M; Bhalla K; Heffner LT; Neely J; Hutcherson D; McLemore M
  • The Improved Efficacy of Bortezomib Containing Induction Regimens (BCIR) Versus Non-Bortezomib Containing Induction Regimens (NBCIR) in Transplant-Eligible Patients with Multiple Myeloma (MM): Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)
    Volume: 118 Page(s): 1709 - 1710
    11/18/2011 Authors: Nooka AK; Kaufman JL; Behera M; Gleason C; Langston A; Steuer CE; Flowers CR; Boise LH; Lonial S
  • Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis
    Volume: 118 Page(s): 855 - 856
    11/18/2011 Authors: Prichard JM; Muppidi S; Flowers CR; Kaufman JL; Lechowicz MJ; Lonial S; Nooka AK; Sinha R; Waller EK; Langston A
  • Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
    Volume: 118 Page(s): 707 - 708
    11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT
  • Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
    Volume: 118 Page(s): 1287 - 1288
    11/18/2011 Authors: Harvey RD; Lonial S; Renfroe H; Sinha R; Flowers CR; Lechowicz MJ; Khoury HJ; Langston A; Waller EK; Kaufman JL
  • A Predictive Model of Overall Survival (OS) for Patients with Relapsed/Refractory Multiple Myeloma (MM) Enrolling in Phase I Clinical Trials
    BLOOD Volume: 118 Page(s): 1691 - 1691
    11/18/2011 Authors: Nooka AK; Muppidi S; Harvey RD; Kaufman JL; Langston A; Lewis C; Boise LH; Flowers CR; Lonial S
  • CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GvHD During High-Risk Unrelated HSCT: A First-in-Disease Feasibility Trial
    Volume: 118 Page(s): 1741 - 1742
    11/18/2011 Authors: Kean LS; Langston A; Qayad M; Khoury HJ; Tiwari D; Couture C; Renfroe H; Sen S; Robertson J; Waller EK
  • Post-Transplant Platelet Recovery Kinetics and Its Association with Overall Survival in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
    Volume: 118 Page(s): 899 - 900
    11/18/2011 Authors: Li J; Deppa JA; Ali Z; Graiser M; Langston A; Gleason C; Thomas J; Waller EK
  • Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
    JAMA Volume: 306 Page(s): 1874 - 1883
    11/02/2011 Authors: Sorror ML; Sandmaier BM; Storer BE; Franke GN; Laport GG; Chauncey TR; Agura E; Maziarz RT; Langston A; Hari P
  • Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Transfusion Volume: 51 Page(s): 2175 - 2182
    10/01/2011 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C
  • Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 11 Page(s): 427 - 432
    10/01/2011 Authors: Arellano M; Bernal-Mizrachi L; Pan L; Tighiouart M; Souza L; Guo X; McLemore M; Lima L; Sunay S; Heffner LT
  • A cluster of mucormycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations.
    Diagn Microbiol Infect Dis Volume: 71 Page(s): 72 - 80
    09/01/2011 Authors: Llata E; Blossom DB; Khoury HJ; Rao CY; Wannemuehler KA; Noble-Wang J; Langston AA; Ribner BS; Lyon GM; Arnold KE
  • Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.
    Haematologica Volume: 96 Page(s): 1113 - 1120
    08/01/2011 Authors: Ram R; Storb R; Sandmaier BM; Maloney DG; Woolfrey A; Flowers MED; Maris MB; Laport GG; Chauncey TR; Lange T
  • The economic costs to United States hospitals of invasive fungal infections in transplant patients.
    Am J Infect Control Volume: 39 Page(s): e15 - e20
    05/01/2011 Authors: Menzin J; Meyers JL; Friedman M; Korn JR; Perfect JR; Langston AA; Danna RP; Papadopoulos G
  • Biomarkers of immune activation to screen for severe, acute GVHD.
    Bone Marrow Transplant Volume: 46 Page(s): 601 - 604
    04/01/2011 Authors: August KJ; Chiang K-Y; Bostick RM; Flanders WD; Waller EK; Langston A; Worthington-White D; Rowland P; Moore KF; Khoury HJ
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.
    Blood Volume: 117 Page(s): 3294 - 3301
    03/24/2011 Authors: Levis M; Ravandi F; Wang ES; Baer MR; Perl A; Coutre S; Erba H; Stuart RK; Baccarani M; Cripe LD
  • Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
    Cancer Volume: 117 Page(s): 1245 - 1252
    03/15/2011 Authors: Lima L; Bernal-Mizrachi L; Saxe D; Mann KP; Tighiouart M; Arellano M; Heffner L; McLemore M; Langston A; Winton E
  • Cost-Effectiveness Analysis of a "Just-In-Time" Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant.
    Volume: 116 Page(s): 923 - 924
    11/19/2010 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Repfroe H; Kaufman JL; Lonial S; Flowers CR; Lechowicz MJ; Langston A
  • Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)
    Volume: 116 Page(s): 978 - 978
    11/19/2010 Authors: Sorror ML; Storer B; Sandmaier BM; Braunert L; Laport GG; Chauncey T; Bredeson C; Maziarz RT; Pulsipher MA; Agura E
  • A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables
    Volume: 116 Page(s): 1415 - 1416
    11/19/2010 Authors: Gyurkocza B; Storb R; Storer BE; Chauncey T; Lange T; Laport GG; Langston A; Pulsipher MA; Bredeson C; Maziarz R
  • Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
    Transfusion Volume: 50 Page(s): 2424 - 2431
    11/01/2010 Authors: Akhtari M; Giver CR; Ali Z; Flowers CR; Gleason CL; Hillyer CD; Kaufman J; Khoury HJ; Langston AA; Lechowicz MJ
  • A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
    10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD
  • Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
    Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
    08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF
  • Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.
    J Clin Oncol Volume: 28 Page(s): 2859 - 2867
    06/10/2010 Authors: Gyurkocza B; Storb R; Storer BE; Chauncey TR; Lange T; Shizuru JA; Langston AA; Pulsipher MA; Bredeson CN; Maziarz RT
  • Safety and efficacy of HiDAC induction in de novo AML patients age 60 and older.
    JOURNAL OF CLINICAL ONCOLOGY Volume: 28
    05/20/2010 Authors: Arellano ML; Pan L; Lima L; Tighiouart M; Heffner LT; Langston AA; McLemore M; Neely J; Winton EF; Khoury HJ
  • Use of posaconazole in the treatment of invasive fungal infections.
    Expert Rev Hematol Volume: 2 Page(s): 619 - 630
    12/01/2009 Authors: Mehta AK; Langston AA
  • Advances in antifungal prophylaxis and empiric therapy in patients with hematologic malignancies.
    Transpl Infect Dis Volume: 11 Page(s): 480 - 490
    12/01/2009 Authors: Murali S; Langston A
  • A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
    Volume: 114 Page(s): 147 - 147
    11/20/2009 Authors: Sandmaier BM; Maris M; Storer B; Vindelov L; Langston A; Wade JC; Bethge WA; Pulsipher M; Lange T; Chauncey T
  • A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias.
    Volume: 114 Page(s): 808 - 808
    11/20/2009 Authors: Garcia-Manero G; Khoury HJ; Borthakur G; Ravandi F; Kadia T; Estrov Z; Jabbour E; Foudray MC; Arellano M; Langston A
  • Anti-Viral Immunity to CMV Reactivation in Allogeneic HSCT Recipients.
    Volume: 114 Page(s): 478 - 479
    11/20/2009 Authors: Hossain MS; Harris WA; Myers SW; Akhtari M; Langston AA; Waller EK
  • Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia.
    Volume: 114 Page(s): 497 - 498
    11/20/2009 Authors: Ram R; Storb RF; Maloney DG; Sandmaier BM; Maris M; Shizuru J; Chauncey T; Langston AA; Georges GE
  • Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse
    Volume: 114 Page(s): 325 - 326
    11/20/2009 Authors: Levis M; Ravandi F; Wang ES; Baer MR; Perl A; Coutre S; Erba H; Stuart RK; Baccarani M; Cripe LD
  • Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients.
    Am J Health Syst Pharm Volume: 66 Page(s): 1711 - 1717
    10/01/2009 Authors: Menzin J; Meyers JL; Friedman M; Perfect JR; Langston AA; Danna RP; Papadopoulos G
  • Extramedullary acute myeloid leukemia and the use of FDG-PET/CT.
    Clin Nucl Med Volume: 34 Page(s): 365 - 366
    06/01/2009 Authors: Rao S; Langston A; Galt JR; Halkar RK
  • Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML)
    Volume: 27
    05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
  • Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
    Volume: 27
    05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
  • Monitoring chronic myeloid leukemia (CML) response to tyrosine kinase inhibitors (TKI) and homoharringtonine (HHT) using peripheral blood (PB) fluorescence in situ hybridization (FISH) and quantitative RT-PCR (Q-PCR): Are bone marrow biopsies still needed?
    J Clin Oncol Volume: 27 Page(s): 7064
    05/20/2009 Authors: Khoury HJ; Lima L; Saxe D; Mann KP; Arellano M; Heffner L; Bernal-Mizrachi L; McLemore M; Langston A; Winton E
  • Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia (AML).
    J Clin Oncol Volume: 27 Page(s): 7070
    05/20/2009 Authors: Arellano ML; Winton E; Pan L; Souza L; Sunay S; Lima L; McLemore M; Heffner LT; Langston A; Khoury HJ
  • Detection of respiratory viruses with a multiplex polymerase chain reaction assay (MultiCode-PLx Respiratory Virus Panel) in patients with hematologic malignancies.
    Leuk Lymphoma Volume: 50 Page(s): 619 - 624
    04/01/2009 Authors: Murali S; Langston AA; Nolte FS; Banks G; Martin R; Caliendo AM
  • THE ECONOMIC COSTS TO US HOSPITALS OF INVASIVE FUNGAL INFECTIONS IN HEMATOPOIETIC STEM CELL AND BONE MARROW TRANSPLANT PATIENTS
    Volume: 15 Page(s): 7 - 7
    02/01/2009 Authors: Menzin J; Jackel JL; Friedman M; Korn JR; Perfect J; Langston A; Prasasd M; Papadopoulos G
  • A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
    CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
    02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT
  • PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
    Volume: 15 Page(s): 154 - 155
    02/01/2009 Authors: Hutcherson DA; Surati M; Sanvidge K; Harvey D; Al-Baldawi RN; Langston A; Flowers C; Lonial S; Kaufman J; Lechowicz MJ
  • EXTRACORPOREAL PHOTOPHERESIS THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSE IS ASSOCIATED WITH CONTENT OF DENDRITIC CELLS AND T-CELLS IN PERIPHERAL BLOOD AT INITIATION OF TREATMENT
    Volume: 15 Page(s): 128 - 129
    02/01/2009 Authors: Akhtari M; Giver CR; Renfroe HM; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL
  • Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.
    Value Health Volume: 12 Page(s): 666 - 673
    01/01/2009 Authors: O'Sullivan AK; Pandya A; Papadopoulos G; Thompson D; Langston A; Perfect J; Weinstein MC
  • Eosinophilic pulmonary syndrome as a manifestation of GVHD following hematopoietic stem cell transplantation in three patients.
    Bone Marrow Transplant Volume: 43 Page(s): 155 - 158
    01/01/2009 Authors: Akhtari M; Langston AA; Waller EK; Gal AA
  • Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment.
    J Antimicrob Chemother Volume: 62 Page(s): 1386 - 1391
    12/01/2008 Authors: Hachem RY; Langston AA; Graybill JR; Perfect JR; Pedicone LD; Patino H; Raad II
  • Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
    Volume: 112 Page(s): 1247 - 1247
    11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R
  • Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia
    Volume: 112 Page(s): 61 - 61
    11/16/2008 Authors: Gyurkocza B; Storb RF; Storer B; Chauncey T; Niederwieser D; Shizuru J; Langston A; Pulsipher M; Bredeson C; Maziarz RT
  • Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged >= 60 Years
    Volume: 112 Page(s): 753 - 754
    11/16/2008 Authors: Sorror ML; Storer B; Sandmaier BM; Maloney DG; Franke G; Shizuru J; Chauncey T; Agura E; Maziarz RT; Sahebi F
  • Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative, Allogeneic Hematopoictic Cell Transplantation (HCT).
    Volume: 112 Page(s): 747 - 748
    11/16/2008 Authors: Sorror ML; Storer B; Sandmaier BM; Maris M; Chauncey T; Maziarz RT; Pulsipher M; Shizuru J; Niederwieser D; Agura E
  • Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease
    Volume: 112 Page(s): 432 - 432
    11/16/2008 Authors: Giver CR; Akhtari M; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL; Vaughn ML
  • A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
    Volume: 112 Page(s): 1144 - 1145
    11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK
  • Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    J Clin Oncol Volume: 26 Page(s): 4912 - 4920
    10/20/2008 Authors: Sorror ML; Storer BE; Sandmaier BM; Maris M; Shizuru J; Maziarz R; Agura E; Chauncey TR; Pulsipher MA; McSweeney PA
  • Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
    Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
    10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP
  • The prognostic significance of donor dendritic cells in allogeneic hematopoietic progenitor cell transplant
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Dejoubner N; Ali Z; Grasier M; Hamilton E; Flowers C; Lonial S; Langston A; Waller EK
  • Induction of GvL after allogeneic stem cell transplantation
    JOURNAL OF CLINICAL ONCOLOGY Volume: 26
    05/20/2008 Authors: Arellano ML; Harris W; Langston A; McMillan S; Rosenthal H; Waller EK
  • Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.
    Cancer Volume: 112 Page(s): 1992 - 2001
    05/01/2008 Authors: Sorror M; Storer B; Sandmaier BM; Maloney DG; Chauncey TR; Langston A; Maziarz RT; Pulsipher M; McSweeney PA; Storb R
  • EARLY DETECTION OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE USING PLASMA MARKERS OF T-CELL ACTIVATION
    Volume: 14 Page(s): 133 - 133
    02/01/2008 Authors: August KJ; Chiang K-J; Bostick RM; Waller EK; Langston A; Khoury HJ; Moore KF; Worthington-White D; Rowland P; Horan JT
  • Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.
    J Clin Oncol Volume: 26 Page(s): 211 - 217
    01/10/2008 Authors: Rezvani AR; Storer B; Maris M; Sorror ML; Agura E; Maziarz RT; Wade JC; Chauncey T; Forman SJ; Lange T
  • Epidemiology of Multiple Myeloma
    Page(s): 9 - 22
    01/01/2008 Authors: Langston AA; Francis D
  • Therapeutic drug monitoring (TDM) of IV busulfan in patients with severe obesity
    Volume: 110 Page(s): 592A - 592A
    11/16/2007 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Sanvidge K; Stricker SR; Langston A; Flowers C; Lechowicz MJ; Waller N; Lonial S
  • Patulin, a mycotoxin, has potent cytotoxic activity on actue lymphoblastic leukemia and induce apoptosis through intrinsic and extrinsic pathways
    Volume: 110 Page(s): 151B - 152B
    11/16/2007 Authors: Wang F; David E; Lonial S; Arellano M; Khoury HJ; Langston A; Lechowicz MJ; Waller N
  • A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 110 Page(s): 288A - 289A
    11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK
  • Long-term follow up of patients (pts) with high-risk chronic lymphocytic leukemia (CLL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT)
    Volume: 110 Page(s): 496A - 496A
    11/16/2007 Authors: Sorror ML; Storer B; Sandmaier BM; Maris MB; Shizuru J; Leis J; Agura E; Chauncey T; Pulsipher M; McSweeney P
  • The effect of rituximab on mobilization with AMD3100 plus G-CSF in patients with relapsed or refractory NHL or HD
    Volume: 110 Page(s): 568A - 568A
    11/16/2007 Authors: Kaufman JL; Cook AM; Flowers C; Langston AA; Lonial S; Lechowicz MJ; Khoury HJ; Calandra G; Waller N
  • Cost-effectiveness of posaconazole vs fluconazole in the prevention of invasive fungal infections among patients with graft-versus-host disease (GVHD) in the US
    Volume: 110 Page(s): 979A - 979A
    11/16/2007 Authors: O'Sullivan AK; Weirstein MC; Pandya A; Thompson D; Langston A; Perfect J; Papadopoulos G
  • Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
    Blood Volume: 110 Page(s): 2744 - 2748
    10/01/2007 Authors: Kahl C; Storer BE; Sandmaier BM; Mielcarek M; Maris MB; Blume KG; Niederwieser D; Chauncey TR; Forman SJ; Agura E
  • Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
    Biol Blood Marrow Transplant Volume: 13 Page(s): 1041 - 1048
    09/01/2007 Authors: Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA
  • Bortezomib,thalidomide and dexamethasone as induction
    Volume: 92 Page(s): 181 - 181
    06/01/2007 Authors: Kaufman JL; Gleason C; Heffner LT; Langston AA; Waller EK; Lonial S
  • Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation--a similar experience.
    Biol Blood Marrow Transplant Volume: 13 Page(s): 746 - 747
    06/01/2007 Authors: Santos EC; Sessions J; Hutcherson D; Flowers C; Langston A; Waller EK
  • Chronic GvHD decreases antiviral immune responses in allogeneic BMT.
    Blood Volume: 109 Page(s): 4548 - 4556
    05/15/2007 Authors: Hossain MS; Roback JD; Pollack BP; Jaye DL; Langston A; Waller EK
  • Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes.
    J Clin Microbiol Volume: 45 Page(s): 1648 - 1651
    05/01/2007 Authors: Ferguson TD; Schniederjan SD; Dionne-Odom J; Brandt ME; Rinaldi MG; Nolte FS; Langston A; Zimmer SM
  • Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. (vol 47, pg 629, 2007)
    TRANSFUSION Volume: 47 Page(s): 952 - 952
    05/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi SS; Teagarden D; Hamilton ES; Waller EK
  • Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
    Transfusion Volume: 47 Page(s): 629 - 635
    04/01/2007 Authors: Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK
  • Posaconazole prophylaxis in haematopoietic stem cell transplant recipients and neutropenic patients: Pharmacokinetics and safety analysis
    Volume: 39 Page(s): S165 - S165
    04/01/2007 Authors: Maertens J; Langston A; Ullmann A; Cornely O; Lipton J; Winston D; Perfect J; Chandrasekar P; Brundage T; Patino H
  • A randomized phase I trial of melphalan plus bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 13 Page(s): 56 - 56
    02/01/2007 Authors: Lonial S; Kaufman J; Langston AA; Khoury HJ; Torre C; Lechowicz MJ; Flowers C; Waller EK
  • Incidence and mortality of invasive fungal infections in high-risk patients receiving posaconazole versus fluconazole or itraconazole prophylaxis
    Volume: 13 Page(s): 33 - 33
    02/01/2007 Authors: Langston A; Lipton JH; Comely OA; Ullnumn AJ; Patino H; Hardalo C; Winston DJ; Chandnisekar P
  • Longer follow up of patients (PTS) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT)
    Volume: 13 Page(s): 133 - 134
    02/01/2007 Authors: Sorror ML; Storer B; Sandmaier BM; Maris MB; Shizuru J; Niederwieser D; Agura E; Chauncey T; Maziarz R; Pulsipher M
  • Impact of posaconazole (POS) vs fluconazole (FLU) on cyclosporine (CSA) and tacrolimus (TAC) dosing in hematopoietic stem cell transplant (HSCT) recipients with graft-vs-host disease (GVHD)
    Volume: 13 Page(s): 76 - 76
    02/01/2007 Authors: Langston A; Lipton JH; Brundage T; Patino H; Ullmann AJ
  • Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
    N Engl J Med Volume: 356 Page(s): 335 - 347
    01/25/2007 Authors: Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N
  • Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience.
    Biol Blood Marrow Transplant Volume: 13 Page(s): 116 - 123
    01/01/2007 Authors: Arellano ML; Langston A; Winton E; Flowers CR; Waller EK
  • Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
    Clin Infect Dis Volume: 44 Page(s): 2 - 12
    01/01/2007 Authors: Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R
  • Postgrafting immunosuppression with prolonged mycophenolate mofetil (MMF) and truncated cyclosporine (CSP) failed to reduce the incidence of graft-versus-host disease (GVHD) after unrelated donor hematopoietic cell transplantation (HCT) with nonmyeloablative conditioning.
    Volume: 108 Page(s): 889A - 889A
    11/16/2006 Authors: Baron F; Sandmaier BM; Storer B; Maris M; Langston A; Niederwieser DW; Petersdorf E; Bethge W; Maziarz RT; McSweeney P
  • The joint role of comorbidity and performance status (PS) in predicting morbidity after allogeneic nonmyeloablative hematopoietic cell transplantation (HCT).
    Volume: 108 Page(s): 180A - 180A
    11/16/2006 Authors: Sorror M; Storer B; Sandmaier BM; Maloney DG; Pulsipher M; Langston A; Maris MB; Niederwieser D; Storb R
  • Impact of revised international working group criteria on lymphoma patients undergoing autologous stem cell transplantation.
    Volume: 108 Page(s): 873A - 873A
    11/16/2006 Authors: Lucas AS; Flowers C; Langston A; Lonial S; Lechowicz MJ; Waller N; Kaufman JL; Jean Khoury H
  • Patients receiving patifermin in conjunction with melphalan 200 required fewer platelet transfusions: Analysis of a retrospective cohort study.
    Volume: 108 Page(s): 407B - 407B
    11/16/2006 Authors: Hutcherson DA; Langston A; Lin CH; Flowers C; Lechowicz MJ; Waller N; Sessions JK; Kaufman JL; Jean Khoury H; Lonial S
  • Cost-effectiveness of posaconazole versus standard azole therapy in the prevention of invasive fungal infections among high-risk neutropenic patients in the US
    Volume: 108 Page(s): 945A - 945A
    11/16/2006 Authors: O'Sullivan AK; Pandya A; Thompson D; Papadopoulos G; Weinstein MC; Perfect JR; Langston A
  • T cell reconstitution in first 200 days post transplantation predicts long term survival in allogeneic hematopoetic progenitor cell transplantation (HPCT).
    Volume: 108 Page(s): 920A - 920A
    11/16/2006 Authors: Vann L; Larks M; Flowers C; Lonial S; Kaufman J; Lechowicz MJ; Langston AA; Khoury J; Waller N
  • Outcomes of allogeneic hematopoietic stem cell transplantation (HCT) after non-myeloablative conditioning in relapsed, refractory, or transformed indolent non-hodgkin lymphoma (NHL).
    Volume: 108 Page(s): 891A - 891A
    11/16/2006 Authors: Rezvani AR; Sandmaier BM; Storer B; Maris M; Agura E; Maziarz R; Wade JC; Chauncey T; Forman SJ; Niederwieser DW
  • Infliximab for the treatment of chronic graft versus host disease.
    Volume: 108 Page(s): 818A - 818A
    11/16/2006 Authors: Tolbert E; Waller N; Khoury HJ; Lechowicz MJ; Flowers C; Lonial S; Vann L; Langston A; Kaufman JL
  • A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus G-CSF) on dendritic cell and T-Cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant.
    Volume: 108 Page(s): 964A - 964A
    11/16/2006 Authors: Lonial S; McMillan S; Torre C; Langston AA; Hamilton E; Cook A; Flowers C; Kaufman JL; Lechowicz MJ; Waller N
  • Deep venous thromboses associated with peripherally inserted central catheters in patients with hematological malignancies.
    Volume: 108 Page(s): 226B - 226B
    11/16/2006 Authors: Tran H; Chamsuddin A; Winton EF; Heffner L; Langston A; Waller N; Arellano M; Khoury HJ
  • Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
    Volume: 108 Page(s): 554A - 554A
    11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ
  • Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
    10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
  • A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.
    J Clin Oncol Volume: 24 Page(s): 17550
    06/20/2006 Authors: Kaufman JL; Waller EK; Torre C; McMillan S; Langston A; Flowers C; Lechowicz M; Tighiouart M; Lonial S
  • Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.
    Clin Infect Dis Volume: 42 Page(s): 1726 - 1734
    06/15/2006 Authors: Raad II; Graybill JR; Bustamante AB; Cornely OA; Gaona-Flores V; Afif C; Graham DR; Greenberg RN; Hadley S; Langston A
  • Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis.
    Arthritis Rheum Volume: 54 Page(s): 1982 - 1986
    06/01/2006 Authors: Nash RA; McSweeney PA; Nelson JL; Wener M; Georges GE; Langston AA; Shulman H; Sullivan KM; Lee J; Henstorf G
  • Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Cancer Volume: 106 Page(s): 2171 - 2180
    05/15/2006 Authors: Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
  • Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Biol Blood Marrow Transplant Volume: 12 Page(s): 454 - 465
    04/01/2006 Authors: Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA
  • Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors
    Volume: 12 Page(s): 132 - 132
    02/01/2006 Authors: Ninan MJ; Arellano M; Philip A; Langston A; Flowers CR; Lonial S; Kaufman J; Lechowicz M; Khoury JH; Roback J
  • Posaconazole (POS) vs fluconazole (FLU) for prophylaxis of invasive fungal infections (IFIs) in allogeneic hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD): A multicenter trial
    Volume: 12 Page(s): 134 - 134
    02/01/2006 Authors: Durrant S; Vesole D; Langston A; Lipton JH; Patino H; Pedicone L; Ullmann AJ
  • Reduced-intensity conditioning permits a significant graft vs leukemia (GvL) effect for acute leukemia
    Volume: 12 Page(s): 69 - 70
    02/01/2006 Authors: Arellano M; Flowers C; Waller E; Lonial S; Kaufman J; Winton E; Khoury H; Langston A
  • Posaconazole as salvage therapy for zygomycosis.
    Antimicrob Agents Chemother Volume: 50 Page(s): 126 - 133
    01/01/2006 Authors: Greenberg RN; Mullane K; van Burik J-AH; Raad I; Abzug MJ; Anstead G; Herbrecht R; Langston A; Marr KA; Schiller G
  • Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma.
    Volume: 106 Page(s): 329A - 329A
    11/16/2005 Authors: Maris MB; Sandmaier BM; Storer B; Agora E; Wade J; Maziarz RT; Forman S; Shizuru J; Chauncey T; Kahl C
  • Efficacy and safety of posaconazole (POS) in the treatment of refractory invasive fungal infections (rIFIs) in patients with underlying renal impairment.
    Volume: 106 Page(s): 430B - 430B
    11/16/2005 Authors: Langston AA; Graham DR; Graybill JR; Pedicone LD; Raad II
  • Efficacy of nonmyeloablative hematopoietic cell transplant (HCT) in secondary myelodysplastic syndrome (MDS) and its impact on the primary disease.
    Volume: 106 Page(s): 234A - 234A
    11/16/2005 Authors: Kerbauy F; Maris M; Storer B; Maloney D; Niederwieser D; Agura E; Pulsipher M; Chauncey T; Maziarz R; Forman S
  • Decreased incidence of relapse in patients with acute leukemia transplanted from matched unrelated donors: Induction of GvL
    Volume: 106 Page(s): 570A - 571A
    11/16/2005 Authors: Arellano ML; Langston A; Lonial S; Flowers C; Khoury JH; Winton E; Waller EK; Mary LJ
  • A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus GCSF) on dendritic cell and T-cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant
    Volume: 106 Page(s): 555A - 555A
    11/16/2005 Authors: Lonial S; Torre C; Langston AA; McMillans S; Hamilton E; Flowers C; Lechowicz MJ; Waller EK
  • Hematopoietic cell transplants (HCT) from HLA-matched related (MRD) and unrelated (URD) donors for patients with hematologic malignancies using low-dose TBI conditioning.
    Volume: 106 Page(s): 194A - 194A
    11/16/2005 Authors: Sandmaier BM; Maris MB; Maloney DG; Gooley TA; Shizuru JA; Niederwieser DW; Chauncey TR; Sahebi F; Agura E; Maziarz RT
  • Relapse free survival of elderly AML patients is comparable to that of younger adults when treated with a modified dose intensive cytarabine regimen.
    Volume: 106 Page(s): 237B - 237B
    11/16/2005 Authors: Langston AA; Heffner LT; Hutcherson D; Neely J; Flowers C; Waller EK; Lonial S; Khoury HJ; Winton E
  • Prognostic significance of early peripheral blood blasts clearance following induction chemotherapy for adult acute myeloid leukemia.
    Volume: 106 Page(s): 236B - 236B
    11/16/2005 Authors: Pakkala S; Winton E; Langston A; Heffner LT; Khoury HJ
  • Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
    Volume: 106 Page(s): 210B - 210B
    11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E
  • Results of a clinical phase I dose-escalation study of cylarabine in combination with fixed dose vinorelbine, paclitaxel, etoposide, and cisplatin (VTEPA) for the treatment of relapsed/refractory lymphoma.
    Volume: 23 Page(s): 607S - 607S
    06/01/2005 Authors: Arellano ML; Lonial S; Langston A; Flowers C; Heffner T; Hutcherson D; Winton E; Waller E
  • Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
    J Clin Oncol Volume: 23 Page(s): 3819 - 3829
    06/01/2005 Authors: Sorror ML; Maris MB; Sandmaier BM; Storer BE; Stuart MJ; Hegenbart U; Agura E; Chauncey TR; Leis J; Pulsipher M
  • Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma
    Volume: 11 Page(s): 6 - 6
    02/01/2005 Authors: Kaufman JL; Lonial S; Hicks M; Langston A; Flowers C; Lechowicz MJ; Khoury H; Waller EK
  • Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma.
    Blood Volume: 104 Page(s): 3535 - 3542
    12/01/2004 Authors: Maris MB; Sandmaier BM; Storer BE; Chauncey T; Stuart MJ; Maziarz RT; Agura E; Langston AA; Pulsipher M; Storb R
  • A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Biol Blood Marrow Transplant Volume: 10 Page(s): 848 - 857
    12/01/2004 Authors: Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
  • A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
    Volume: 104 Page(s): 502A - 502A
    11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ
  • Unrelated donor peripheral blood stem cell (PBSC) transplantation using nonmyeloablative conditioning and mycophenolate mofetil (MMF) TID results in high engraftment rates.
    Volume: 104 Page(s): 503A - 503A
    11/16/2004 Authors: Maris MB; Sandmaier BM; Storer B; Shizuru J; Maloney D; Agura E; Niederwieser D; Pulsipher M; Maziarz RT; McSweeney P
  • Nonmyeloablative conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related or unrelated donors for chemotherapy-refractory chronic lymphocytic leukemia (CLL).
    Volume: 104 Page(s): 639A - 639A
    11/16/2004 Authors: Sorror M; Maris M; Storer B; Sandmaier B; Stuart M; Hegenbart U; Agura E; Chauncey T; Leis J; Pulsipher M
  • A randomized trial to evaluate the impact of cytokines on dendritic cell, T-cell and T-cell function when mobilizing normal donors for allogeneic progenitor cell transplant: An interim analysis.
    Volume: 104 Page(s): 780A - 780A
    11/16/2004 Authors: Lonial S; Torre C; Hicks M; Mcmillan S; Langston AA; Flowers CR; Lechowicz MJ; Waller EK
  • Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma
    Volume: 104 Page(s): 231A - 231A
    11/16/2004 Authors: Maris MB; Sandmaier BM; Storer BE; Chauncey T; Stuart MJ; Maziarz RT; Agura E; Langston AA; Pulsipher M; Storb R
  • Predictors of more rapid lymphoid reconstitution after allogeneic transplantation
    Volume: 104 Page(s): 864A - 864A
    11/16/2004 Authors: Arellano ML; Moore SG; Kudchadkar R; Flowers CR; Langston AA; Lonial S; Lechowicz MJ; Waller EK
  • Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
    Volume: 33 Page(s): 196 - 197
    11/01/2004 Authors: Waller E; Giver C; Somani J; Langston A; Lonial S; Roback J; Jian ML; Hossain M; Redei I
  • Update on myelodysplastic syndromes: new approaches to classification and therapy.
    Semin Oncol Volume: 31 Page(s): 72 - 79
    04/01/2004 Authors: Langston AA; Walling R; Winton EF
  • Update on myelodysplastic syndromes: New approaches to classification and therapy
    Volume: 31 Page(s): 72 - 79
    04/01/2004 Authors: Langston AA; Walling R; Winton EF
  • Update in acute leukemia 2003: A risk adapted approach to acute myeloblastic leukemia in adults
    Volume: 31 Page(s): 80 - 86
    04/01/2004 Authors: Winton EF; Langston AA
  • Update in acute leukemia 2003: a risk adapted approach to acute myeloblastic leukemia in adults.
    Semin Oncol Volume: 31 Page(s): 80 - 86
    04/01/2004 Authors: Winton EF; Langston AA
  • Optimization of chemo-mobilization of autologous blood hematopoietic progenitor cell grafts
    Volume: 10 Page(s): 64 - 65
    02/01/2004 Authors: Hicks ML; Lonial S; Langston A; Smith KJ; Sai SM; Hamilton ES; Waller EK
  • Retrospective review of therapy with reduced dose rasburicase in adults with hyperuricemia associated with malignancy
    Volume: 10 Page(s): 104 - 104
    02/01/2004 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Shayani S; Barreras AM; Bucur SZ; Heffner LT; Langston AA
  • Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
    Blood Cells Mol Dis Volume: 33 Page(s): 233 - 237
    01/01/2004 Authors: Waller EK; Giver CR; Rosenthal H; Somani J; Langston AA; Lonial S; Roback JD; Li J-M; Hossain MS; Redei I
  • Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: An externally controlled blinded trial.
    Volume: 102 Page(s): 195A - 196A
    11/16/2003 Authors: Walsh T; Patterson T; Langston A; van Burik J; Louie A; Herbrecht R; Hadley S; Perfect J; Hsu C; Gogate J
  • Safety of voriconazole after autologous and allogeneic stem cell transplantation.
    Volume: 102 Page(s): 454B - 454B
    11/16/2003 Authors: Restrepo MH; Langston AA; Shayani S; Waller EK; Lonial S
  • A phase I trial of Ara-C, Topotecan, and Gemtuzumab Ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
    Volume: 102 Page(s): 333B - 333B
    11/16/2003 Authors: Langston AA; Tanner A; Lonial S; Heffner LT; Smith K; Bucur S; Waller EK; Redei I; Winton E
  • Modulation of allogeneic PBPC graft contents using G-CSF or G-CSF+GM-CSF: Preliminary results from a randomized trial.
    Volume: 102 Page(s): 953A - 953A
    11/16/2003 Authors: Lonial S; Torre C; Hicks M; Tanner A; Langston AA; Redei I; Waller EK
  • Optimal timing for chemotherapy and cytokine mobilization of autologous blood hematopoietic progenitor cells.
    Volume: 102 Page(s): 419B - 419B
    11/16/2003 Authors: Hicks ML; Lonial S; Langston A; Smith KJ; Sai SM; Hamilton ES; Waller EK
  • Early autologous transplantation for mantle cell lymphoma may improve long term disease-free survival.
    Volume: 102 Page(s): 734A - 735A
    11/16/2003 Authors: Murali S; Lonial S; Redei I; Smith K; Waller EK; Heffner LT; Bucur S; Winton E; Manion K; Langston A
  • A phase I study of dose escalated cytarabine in combination with a modified ESHAP-like regimen, paclitaxel, and vinorelbine (VTEPA) for the treatment of relapsed/refractory lymphoma.
    Volume: 102 Page(s): 293B - 293B
    11/16/2003 Authors: Lonial S; Tanner A; Langston AA; Redei I; Heffner LT; Bucur SZ; Hutcherson D; Winton E; Waller EK
  • Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation.
    Biol Blood Marrow Transplant Volume: 9 Page(s): 460 - 471
    07/01/2003 Authors: Waller EK; Langston AA; Lonial S; Cherry J; Somani J; Allen AJ; Rosenthal H; Redei I
  • Three methods of T-cell depletion of HPCT products: Analysis of CD34+ cell and lymphocyte purity and recovery.
    Volume: 100 Page(s): 835A - 836A
    11/16/2002 Authors: Lonial S; Rizzieri DA; Koh LP; Jones M; Langston AA; Redei I; Long GD; Gasparetto C; Vredenburgh JJ; Waller EK
  • Treatment of severe systemic sclerosis with allogenic marrow transplantation.
    Volume: 100 Page(s): 460B - 461B
    11/16/2002 Authors: Nash RA; McSweeney PA; Storb R; Sullivan KM; Langston A; Sunderhaus JL; Wener M; Furst D
  • Effect of donor dendritic cells on overall survival and incidence of GvHD after allogeneic HPCT from HLA matched sibling donors.
    Volume: 100 Page(s): 420A - 421A
    11/16/2002 Authors: Gladney SP; Waller EK; Redei I; Langston AA; Lonial S
  • Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma.
    Volume: 100 Page(s): 178A - 178A
    11/16/2002 Authors: Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S
  • Rapid hematopoietic engraftment following fractionated TBI conditioning and transplantation with CD34(+) enriched hematopoietic progenitor cells from partially mismatched related donors.
    Bone Marrow Transplant Volume: 30 Page(s): 335 - 340
    09/01/2002 Authors: Redei I; Langston AA; Lonial S; Cherry JK; Allen AJ; Hamilton E; Jones M; Bartlett VM; Waller EK
  • Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation.
    Blood Volume: 99 Page(s): 1085 - 1088
    02/01/2002 Authors: Langston AA; Redei I; Caliendo AM; Somani J; Hutcherson D; Lonial S; Bucur S; Cherry J; Allen A; Waller EK
  • Granulomatous Pneumocystis carinii pneumonia complicating hematopoietic cell transplantation.
    Pathol Res Pract Volume: 198 Page(s): 553 - 558
    01/01/2002 Authors: Gal AA; Plummer AL; Langston AA; Mansour KA
  • Yield of surveillance blood cultures in patients on corticosteroids for graft-versus-host disease.
    BLOOD Volume: 98 Page(s): 362B - 362B
    11/16/2001 Authors: Somani J; Teagarden D; Mossavi-sai S; Thourani J; Redei I; Lonial S; Waller EK; Langston AA
  • CD34 selection of peripheral blood progenitor cells for autologous transplant in myeloma and amyloidosis is associated with an increased risk of post-transplant varicella Zoster.
    BLOOD Volume: 98 Page(s): 392A - 392A
    11/16/2001 Authors: Smith KJ; Hamilton ES; Waller EK; Langston AA; Redei I; Lonial S; Heffner LT
  • Comparison of partially mismatched related donor (PMRD) graft vs volunteer unrelated donor (VUD) transplant for high risk hematologic malignancies.
    BLOOD Volume: 98 Page(s): 386B - 386B
    11/16/2001 Authors: Redei I; Langston AA; Jones M; Tanner A; Teagarden D; Lonial S; Cherry J; Bartlett V; Waller EK
  • Infectious outcomes after alternative donor stem cell transplantation: A retrospective cohort study.
    BLOOD Volume: 98 Page(s): 205A - 205A
    11/16/2001 Authors: Somani J; Redei I; Cherry J; Tanner A; Lonial S; Bartlett V; Manion K; Waller EK; Langston AA
  • Salvage therapy with Infliximab for patients with severe acute and chronic GvHD.
    BLOOD Volume: 98 Page(s): 399A - 399A
    11/16/2001 Authors: Redei I; Knoche J; Tanner AR; Langston AA; Lonial S; Cherry JK; Sai SM; Waller EK
  • Thymoglobulin pharmicokinetics and immune reconstitution in recipients of T-cell depleted CD34+transplants from HLA mis-matched donors.
    BLOOD Volume: 98 Page(s): 670A - 670A
    11/16/2001 Authors: Waller N; Langston A; Lonial S; Allen A; Cherry J; Rosenthal HS; Redei I
  • Non-fatal Veno-Occlusive disease in non-transplant patients after treatment of relapsed AML with Mylotarg (gemtuzumab ozogamicin).
    BLOOD Volume: 98 Page(s): 201B - 202B
    11/16/2001 Authors: Langston AA; Feinstein B; Hutcherson D; Heffner LT; Redei I; Smith K; Lonial S; Bucur S; Jones A; Waller EK
  • Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation.
    Blood Volume: 97 Page(s): 2948 - 2956
    05/15/2001 Authors: Waller EK; Rosenthal H; Jones TW; Peel J; Lonial S; Langston A; Redei I; Jurickova I; Boyer MW
  • Acyclovir (ACV)-resistant herpes simplex virus (HSV) after T- and B-cell depleted haploidentical stem cell transplantation (SCT).
    BLOOD Volume: 96 Page(s): 193A - 193A
    11/16/2000 Authors: Langston A; Redei I; Bucur S; Cherry J; Allen A; Thourani J; Teagarden D; Mossavi-Sai S; Hutcherson D; Waller EK
  • Chronic GVHD (cGVHD) after matched sibling BMT is predicted by the number of transplanted donor NK-like T cells.
    BLOOD Volume: 96 Page(s): 200A - 200A
    11/16/2000 Authors: Langston A; Jones TW; Rosenthal H; Redei I; Lonial S; Waller EK
  • Effective T cell depletion of G-CSF mobilized haploidentical PBSC graft with combined positive/negative immunomagnetic selection using Isolex 300i system version 2.5.
    BLOOD Volume: 96 Page(s): 185A - 185A
    11/16/2000 Authors: Redei I; Langston AA; Cherry JK; Hamilton ES; Jones ML; Waller EK
  • Sequential CD34+and CD3+allogeneic cell transplants in patients with poor risk hematologic malignancies.
    BLOOD Volume: 96 Page(s): 359B - 359B
    11/16/2000 Authors: Waller EK; Langston AA; Bucur S; Lonial S; Cherry J; Feinstein B; Redei I
  • Modified perugia approach for haploindentical related donor transplantation for adults with poor prognostic hematologc malignancies.
    BLOOD Volume: 96 Page(s): 209A - 209A
    11/16/2000 Authors: Redei I; Langston AA; Cherry JK; Allen AJ; Bartlett VM; Waller EK
  • Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature.
    Bone Marrow Transplant Volume: 24 Page(s): 1337 - 1341
    12/01/1999 Authors: Lonial S; Bilodeau PA; Langston AA; Lewis C; Mossavi-Sai S; Holden JT; Waller EK
  • Unrelated donor marrow transplantation using a preparative regimen of fractionated TBI, thiotepa, fludarabine, and ATG.
    BLOOD Volume: 94 Page(s): 392B - 392B
    11/15/1999 Authors: Langston AA; Redei I; Bucur S; Allen A; Cherry JK; Bartlett V; Waller EK
  • Salvage therapy with mycophenolate mofetil (MMF) for patients with severe chronic GVHD.
    BLOOD Volume: 94 Page(s): 159A - 159A
    11/15/1999 Authors: Redei I; Langston AA; Cherry JK; Allen A; Waller EK
  • Busulfan/cyclophosphamide/fludarabine (BCF) conditioning prior to volunteer unrelated donor (VUD) bmt for patients with hematologic malignancies: A potential alternative to TBI containing preparative regimens.
    BLOOD Volume: 94 Page(s): 567A - 567A
    11/15/1999 Authors: Redei I; Langston AA; Bartlett V; Cherry JK; Allen A; Bucur S; Waller EK
  • Modified high dose Ara-C (mHiDAC) and daunorubicin as induction therapy for newly diagnosed AML without t(15;17).
    BLOOD Volume: 94 Page(s): 233B - 233B
    11/15/1999 Authors: Lonial S; Langston AA; Bhalla K; Smith KJ; Heffner LT; Bucur S; Hutcherson DA; Winton EF
  • Survival analysis of allogeneic bone marrow transplant (BMT) with and without GM-CSF support, a retrospective analysis of 182 patient.
    BLOOD Volume: 94 Page(s): 151A - 151A
    11/15/1999 Authors: Lonial S; Langston AA; Jones TW; Ennis SD; Waller EK
  • Autologous peripheral blood stem cell (PBSC) transplantation in AML: Outcome and flow cytometric analysis of the PBSC product.
    BLOOD Volume: 94 Page(s): 398B - 398B
    11/15/1999 Authors: Bucur SZ; Heffner LT; Langston AA; Redei J; Waller EK; Winton EF; Holden JT; Smith KJ
  • Neurotoxicity associated with the use of tacrolimus following bone marrow transplantation: Noncorrelation with tacrolimus serum level.
    BLOOD Volume: 94 Page(s): 334A - 334A
    11/15/1999 Authors: Redei I; Langston AA; Cherry JK; Allen A; Waller EK
  • Allogeneic cell transplantation with rhG-CSF mobilized CD34+selected PBPC in conjunction with adoptive immunotherapy for adults with hematologic malignancy.
    BLOOD Volume: 94 Page(s): 157A - 157A
    11/15/1999 Authors: Redei I; Langston AA; Cherry JK; Allen A; Bucur S; Waller EK
  • A novel retinal degeneration locus identified by linkage and comparative mapping of canine early retinal degeneration.
    Genomics Volume: 59 Page(s): 134 - 142
    07/15/1999 Authors: Acland GM; Ray K; Mellersh CS; Langston AA; Rine J; Ostrander EA; Aguirre GD
  • Evaluation of the APOH gene as a positional candidate for prcd in dogs.
    Invest Ophthalmol Vis Sci Volume: 40 Page(s): 1229 - 1237
    05/01/1999 Authors: Gu W; Ray K; Pearce-Kelling S; Baldwin VJ; Langston AA; Ray J; Ostrander EA; Acland GM; Aguirre GD
  • Toward a framework linkage map of the canine genome.
    J Hered Volume: 90 Page(s): 7 - 14
    01/01/1999 Authors: Langston AA; Mellersh CS; Wiegand NA; Acland GM; Ray K; Aguirre GD; Ostrander EA
  • Survival after allogeneic bone marrow transplantation (BMT) is predicted by the number of transplanted donor CD34+ cells and donor dendritic cell progenitors (DCPs).
    BLOOD Volume: 92 Page(s): 495A - 495A
    11/15/1998 Authors: Waller EK; Lynn MJ; Boyer M; Jones TW; Rosenthal H; Langston A; Lopez R; Bucur S; Hillyer C; Redei I
  • Identification of a RAPD marker linked to progressive rod-cone degeneration in dogs.
    Mamm Genome Volume: 9 Page(s): 740 - 744
    09/01/1998 Authors: Gu W; Acland GM; Langston AA; Ostrander EA; Aguirre GD; Ray K
  • Linkage analysis and comparative mapping of canine progressive rod-cone degeneration (prcd) establishes potential locus homology with retinitis pigmentosa (RP17) in humans.
    Proc Natl Acad Sci U S A Volume: 95 Page(s): 3048 - 3053
    03/17/1998 Authors: Acland GM; Ray K; Mellersh CS; Gu W; Langston AA; Rine J; Ostrander EA; Aguirre GD
  • A linkage map of the canine genome.
    Genomics Volume: 46 Page(s): 326 - 336
    12/15/1997 Authors: Mellersh CS; Langston AA; Acland GM; Fleming MA; Ray K; Wiegand NA; Francisco LV; Gibbs M; Aguirre GD; Ostrander EA
  • Construction of a panel of canine-rodent hybrid cell lines for use in partitioning of the canine genome.
    Genomics Volume: 46 Page(s): 317 - 325
    12/15/1997 Authors: Langston AA; Mellersh CS; Neal CL; Ray K; Acland GM; Gibbs M; Aguirre GD; Fournier RE; Ostrander EA
  • Linkage analysis in early retinal degeneration
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE Volume: 38 Page(s): 1508 - 1508
    03/15/1997 Authors: Acland GM; Ostrander EA; Mellersh CS; Langston AA; Rine J; Neff M; Ray K; Aguirre GD
  • Hereditary ovarian cancer.
    Curr Opin Obstet Gynecol Volume: 9 Page(s): 3 - 7
    02/01/1997 Authors: Langston AA; Ostrander EA
  • Breast cancer and BRCA1 mutations.
    N Engl J Med Volume: 334 Page(s): 1197 - 1198
    05/02/1996 Authors: Offit K
  • Breast cancer and BRCA1 mutations - Reply
    NEW ENGLAND JOURNAL OF MEDICINE Volume: 334 Page(s): 1200 - 1200
    05/02/1996 Authors: Langston AA; Malone KE; Ostrander EA
  • A class of highly polymorphic tetranucleotide repeats for canine genetic mapping.
    Mamm Genome Volume: 7 Page(s): 359 - 362
    05/01/1996 Authors: Francisco LV; Langston AA; Mellersh CS; Neal CL; Ostrander EA
  • Germ-line BRCA1 mutations in selected men with prostate cancer.
    Am J Hum Genet Volume: 58 Page(s): 881 - 885
    04/01/1996 Authors: Langston AA; Stanford JL; Wicklund KG; Thompson JD; Blazej RG; Ostrander EA
  • Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita.
    Br J Haematol Volume: 92 Page(s): 758 - 765
    03/01/1996 Authors: Langston AA; Sanders JE; Deeg HJ; Crawford SW; Anasetti C; Sullivan KM; Flowers ME; Storb R
  • BRCA1 mutations in a population-based sample of young women with breast cancer.
    N Engl J Med Volume: 334 Page(s): 137 - 142
    01/18/1996 Authors: Langston AA; Malone KE; Thompson JD; Daling JR; Ostrander EA
  • Tissue-specific extinguisher loci in the human genome: a screening study based on random marking and transfer of human chromosomes.
    Somat Cell Mol Genet Volume: 20 Page(s): 215 - 231
    05/01/1994 Authors: Shapero MH; Langston AA; Fournier RE
  • Miliary tuberculosis: epidemiology, clinical manifestations, diagnosis, and outcome.
    Rev Infect Dis Volume: 12 Page(s): 583 - 590
    01/01/1990 Authors: Kim JH; Langston AA; Gallis HA
  • Herpes simplex virus encephalitis: the need for early diagnosis.
    N C Med J Volume: 47 Page(s): 17 - 19
    01/01/1986 Authors: Shaw GL; Langston AA
  • Antibodies to bovine leukemia virus in a leukosis dairy herd and suggestions for control of the infection.
    Can J Comp Med Volume: 43 Page(s): 173 - 179
    04/01/1979 Authors: Ferdinand GA; Langston A; Ruppanner R; Drlica S; Theilen GH; Behymer DE
  • Comparison of production variables of bovine leukemia virus antibody-negative and antibody-positive cows in two California dairy herds.
    Am J Vet Res Volume: 39 Page(s): 1093 - 1098
    07/01/1978 Authors: Langston A; Ferdinand GA; Ruppanner R; Theilen GH; Drlica S; Behymer D
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements